摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-Methoxy-4-methylpentan-2-ol | 53892-33-4

中文名称
——
中文别名
——
英文名称
1-Methoxy-4-methylpentan-2-ol
英文别名
——
1-Methoxy-4-methylpentan-2-ol化学式
CAS
53892-33-4
化学式
C7H16O2
mdl
——
分子量
132.2
InChiKey
PUBJOYLZVVHMIK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.1
  • 重原子数:
    9
  • 可旋转键数:
    4
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    29.5
  • 氢给体数:
    1
  • 氢受体数:
    2

文献信息

  • [EN] OXAZOLIDINONES AS MODULATORS OF MGLUR5<br/>[FR] OXAZOLIDINONES UTILISÉES EN TANT QUE MODULATEURS DE MGLUR5
    申请人:BRISTOL MYERS SQUIBB CO
    公开号:WO2015054103A1
    公开(公告)日:2015-04-16
    The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, agonists and partial agonists for the mGluR5 receptor and may be useful for the treatment of various disorders of the central nervous system.
    该披露通常涉及到公式I的化合物,包括它们的盐,以及使用这些化合物的组合物和方法。这些化合物是mGluR5受体的配体、激动剂和部分激动剂,可能对中枢神经系统的各种疾病的治疗有用。
  • Benzamide Inhibitors of the P2X7 Receptor
    申请人:DOMBROSKI MARK A.
    公开号:US20090042886A1
    公开(公告)日:2009-02-12
    The present invention provides benzamide inhibitors of the P2X 7 receptor of the formula: wherein R 1 -R 3 are as defined herein. The compounds of the invention are useful in the treatment of IL-1 mediated disorders, including, without limitation, inflammatory diseases such as osteoarthritis and rheumatoid arthritis; allergies, asthma, COPD, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.
    本发明提供了P2X7受体的苯甲酰胺抑制剂,其化学式如下:其中R1-R3的定义如本文所述。该发明的化合物对于治疗IL-1介导的疾病有用,包括但不限于炎症性疾病,如骨关节炎和类风湿性关节炎;过敏、哮喘、慢性阻塞性肺疾病、癌症、脑卒中或心脏病发作中的再灌注或缺血、自身免疫性疾病和其他疾病。
  • Benzamide Inhibitors of The P2X7 Receptor
    申请人:Dombrowski A. Mark
    公开号:US20070281939A1
    公开(公告)日:2007-12-06
    The present invention provides benzamide inhibitors of the P2X 7 receptor of the formula: wherein R 1 -R 3 are as defined herein. The compounds of the invention are useful in the treatment of IL-1 mediated disorders, including, without limitation, inflammatory diseases such as osteoarthritis and rheumatoid arthritis; allergies, asthma, COPD, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.
    本发明提供了P2X7受体的苯甲酰胺抑制剂,其化学式如下:其中R1-R3的定义如本文所述。本发明的化合物可用于治疗IL-1介导的疾病,包括但不限于炎症性疾病,如骨关节炎和类风湿性关节炎;过敏,哮喘,慢性阻塞性肺疾病,癌症,中风或心脏病发作中的再灌注或缺血,自身免疫性疾病和其他疾病。
  • PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS
    申请人:Gibbons Paul
    公开号:US20120190665A1
    公开(公告)日:2012-07-26
    A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R 1 , R 2 and R 3 are defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient are disclosed.
    公式I的化合物、对映异构体、顺反异构体、互变异构体或其药学上可接受的盐,其中R1、R2和R3的定义如本文所述,可用作一种或多种Janus激酶的抑制剂。本文还揭示了一种包括公式I的化合物和药学上可接受的载体、辅料或载体的药物组合物,以及治疗或减轻患者对Janus激酶活性抑制响应的疾病或状况的方法。
  • PYRAZOLYL DERIVATIVES AS SYK INHIBITORS
    申请人:Merck Sharp & Dohme Corp.
    公开号:US20150191461A1
    公开(公告)日:2015-07-09
    The present invention provides novel pyrazole derivatives of formula I which are potent inhibitors of spleen tyrosine kinase, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD, rheumatoid arthritis, and cancer.
    本发明提供了公式I的新型吡唑衍生物,它们是脾酪氨酸激酶的有效抑制剂,并可用于治疗和预防由该酶介导的疾病,如哮喘、慢性阻塞性肺疾病、类风湿性关节炎和癌症。
查看更多